Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Administration (FDA) as 3 separate brand name medications—Ozempic®, Wegovy®, and Rybelsus®. Each brand name comes with its own associated indications, preparations, and dosages to consider. The Rybelsus® tablet brand demonstrates efficacy in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). Ozempic® injectable brand provides an additional indication of reducing the risk of major adverse cardiovascular events in patients with and without T2DM. In a recent development, semaglutide received FDA approval under the brand name Wegovy®, which is an injection used for promoting weight loss in individuals dealing with obesity and overweight. Due to the increased complexity involved, special attention is necessary for every FDA-approved indication and current off-label use.
The numerous and evolving benefits of semaglutide are complicated due to differences in dosing and available preparations. Clinicians must obtain a firm grasp of how semaglutide may be used safely and effectively. This activity aims to provide a clear understanding of semaglutide, including its indications, benefits, mechanisms of action, potential adverse effects, monitoring recommendations, and general pharmacological characteristics. This activity also explores the essential role of the interprofessional healthcare team in improving patient outcomes with semaglutide.
Objectives:
-
Differentiate between the various brand name formulations of semaglutide (Ozempic®, Wegovy®, and Rybelsus®) and their respective indications, dosing regimens, and preparations.
-
Implement semaglutide therapy according to recommended dosing schedules and administration methods, ensuring proper patient education on injection techniques or oral administration.
-
Apply knowledge of semaglutide’s mechanisms of action and pharmacological characteristics to optimize treatment outcomes and minimize risks.
-
Collaborate with other healthcare professionals and coordinate care transitions and follow-up appointments to ensure continuity of semaglutide therapy and ongoing monitoring of treatment efficacy and safety.
